Recently, there has been good news in the field of clinical and cooperation in the field of domestic anti-tumor drugs

At present, anti-tumor drugs have become a large-scale and fast-growing therapeutic field
in the world, including the Chinese pharmaceutical market.
Data show that in 2021, the global anti-tumor drug market sales have reached 187 billion US dollars, with a stable growth rate of more than 10%; In China, the sales of anti-tumor drugs market have also been comparable to the scale of the anti-infective drug market
.
It is worth noting that with the continuous expansion of the anti-tumor drug market, many domestic pharmaceutical companies and research institutions are also accelerating the layout of the market, and affected by this, there is good news in oncology drugs in the near future
.
Clinical Recently, the Class 1 new drugs TR115 and TR64, independently developed by the pharmaceutical team of Liu Qingsong of the Institute of Health and Medical Technology of the Hefei Institute of Physical Sciences, Chinese Academy of Sciences, were approved by the Center for Drug Evaluation of the National Medical Products Administration to carry out clinical trials
for non-Hodgkin lymphoma and advanced malignant solid tumors on the same day 。 Among them, TR64 is a dual-target kinase inhibitor, which has a strong tumor inhibitor effect on various malignant solid tumor models such as liver cancer, breast cancer, and gastrointestinal stromal tumor by directly inhibiting tumor growth and regulating the tumor microenvironment, and is expected to become a new generation of targeted therapy drugs
for the treatment of colorectal cancer, liver cancer, breast cancer, etc.
TR115 is a highly active and selective novel small molecule inhibitor
of epigenetic targets.
The results of preclinical studies show that TR115 can significantly inhibit the proliferation of related tumor cells, have good pharmacokinetic properties and safety window, and can inhibit tumor growth dose-dependently, which is expected to become a new generation of targeted therapy drugs
for the treatment of diffuse large B-cell lymphoma and ovarian cancer.
Cooperation On November 6, AstraZeneca and Dunfu Medical Group held a strategic cooperation award ceremony at the AstraZeneca booth at the CIIE, and the two parties will carry out a number of innovative cooperation
in the field of medicine and health based on their respective advantages in terms of platform and resources.
Among them, it is worth noting that the two parties will also work together to accelerate the landing and application
of new anti-tumor drugs in China.
It is reported that through this cooperation, AstraZeneca and Dunfu Medical will further accelerate the landing and application of innovative drugs in China, jointly promote the model of tumor specific drug management services, and provide innovative patient service solutions.
On the same day, at the 5th China International Import Expo, Burnstone Medical and Eli Lilly reached a cooperation intention
for companion diagnosis.
The two parties will integrate the superior resources of all parties in the field of tumor diagnosis and treatment, focus on the management needs of patients throughout the course of the disease, jointly promote the popularization of innovative oncology drugs, and help the new development
of precision diagnosis and treatment of cancer in China.
Commercialization Hansen Pharmaceutical announced that on November 14, 2022, Hansen (Shanghai) Health Technology Co.
, Ltd.
(licensee), a wholly-owned subsidiary of the Company, entered into a license agreement
with Pumeis Biotechnology (Zhuhai) Co.
, Ltd.
Under the license agreement, Licensee obtains an exclusive license from Pumeis to develop and commercialize PM1080
in China, including Hong Kong, Macau and Taiwan.
It is reported that PM1080 is an EGFR/cMet bispecific antibody drug, which has great therapeutic potential to block the signaling of EGFR and c-Met at the same time, inhibit tumor growth and survival, and is currently in the preclinical research stage
.
Pumeis will receive an upfront payment of RMB50 million and will be eligible for milestone payments of up to RMB1.
418 billion when commercializing the indications specified in the license agreement, as well as tiered royalties
based on future net sales in China.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.